PCREMEP Stock Latest News
Private CompaniesRemepy Highlights Hybrid Drug Model at HLTH20261h agoREMEP
Private CompaniesRemepy Hybrid Drug Platform Nominated for 2026 Prix Galien Bridges Award4d agoREMEP
Private CompaniesRemepy Highlights Patient-Focused Engagement in Parkinson’s Community1M agoREMEP
Private CompaniesRemepy Gains Industry Recognition for Hybrid Drug Approach in Digital Health1M agoREMEP
Private CompaniesRemepy Strengthens Clinical Leadership Ahead of Parkinson’s Phase III Trial2M agoREMEP
Private CompaniesRemepy Advances Hybrid Parkinson’s Therapy Toward Phase III Development2M agoREMEP
Private CompaniesRemepy’s TGCT & Me App Gains UX Design Award Nomination3M agoREMEP
Private CompaniesRemepy Advances Hybridopa Parkinson’s Program Toward Phase 3 Design3M agoREMEP
Private CompaniesDigital Support Initiative Targets Rare Sarcoma Patients3M agoREMEP
Private CompaniesRemepy – Weekly Recap4M agoREMEPPrivate CompaniesRemepy Advances Hybridopa With New Parkinson’s Data and Hybrid Drug Visibility4M agoREMEP
Private CompaniesRemepy Highlights New Parkinson’s Data as It Prepares Hybridopa for Phase 34M agoREMEP
Private CompaniesRemepy Showcases Hybrid Drug Concept at Tech Tour Growth Health Event4M agoREMEP
Private CompaniesRemepy Advances Hybridopa Toward Phase 3 as TGCT App Gains Clinical Spotlight5M agoREMEP
Private CompaniesRemepy Highlights Phase IIa Hybridopa Data and Targets Phase 3 Parkinson’s Trial in Q35M agoREMEPPrivate CompaniesRemepy Advances Phase 3 Parkinson’s Plans and Expands TGCT Digital Footprint5M agoREMEP
Private CompaniesPhase 3 Parkinson’s Trial Engagement Signals Advancing Pipeline at Remepy5M agoREMEP



